Entyvio is a brand-name prescription biologic drug. It contains the active ingredient vedolizumab. Biosimilars are generic versions of biologic medications, but only the brand-name version of this ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...

Studies, presented at the 25th UEG Week, demonstrated the effectiveness of Takeda’s Entyvio in treating ulcerative colitis and Crohn’s disease, IBD News Today reports. From May 2014 to January 2017, ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Patients with Crohn’s disease are now likely to get National Health Service access to Takeda’s biologic Entyvio in England and Wales following a u-turn by the National Institute for Health and Care ...

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the ...

The U.S. Food and Drug Administration (FDA) accepted for review Takeda's resubmitted application seeking approval for subcutaneous (SC) administration of Entyvio as a maintenance therapy in adults ...

The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...

Fresenius Kabi is expanding its growing biopharma portfolio through a new licensing agreement with Polpharma Biologics S.A. Fresenius Kabi will commercialize Polpharma Biologics’ vedolizumab ...